Inclusion Criteria:  Sign the informed consent form and fully understand the test content, process and possible adverse reactions, and be able to complete the study according to the test plan requirements; Age≥18 years and ≤50 years, healthy male subjects; Weight ≥ 50kg and ≤ 100kg,BMI≥ 19kg/m2 and < 28 kg/m2 Clinical examinations in the screening period are normal or abnormal without clinical significance. Agree to take effective contraceptive measures throughout the study period and until at least 6 months after receiving the last dose of study drug  Exclusion Criteria:  Any prior VEGF(vascular endothelial growth factor) and VEGFR(Vascular Endothelial Growth Factor Receptor) antibody or protein treatment within one year. Serious, non-healing wound, active ulcer, or untreated bone fracture, or major surgical procedure within 2 months prior to randomization or anticipation of need for major surgery during the course of the study or 2 months after end of the study. Use Rx or OTC drugs or nutritional health products within 5 half-lives or within 2 weeks before the first dose of study drug (According to the longer time).Herbal supplements need to stop at 28 days before the first dose of study drug. Positive hepatitis b surface antigen (HBsAg), hepatitis c virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody or syphilis. Known hypersensitivity to bevacizumab or any excipients, known allergic disease or allergic constitution. History of blood donation within 3 months before the first dose of study drug. Treatment with any other investigational agent or participation in another clinical trial within 3 months prior to screening.